Aripaka, K., Gudey, S.K., Zang, G., Schmidt, A., Åhrling, S.S., Österman, L., Bergh, A., von Hofsten, J., Landström, M. (2019) TRAF6 function as a novel co-regulator of Wnt3a target genes in prostate cancer. EBioMedicine. 45:192-207
|
Boysen, G., Barbieri, C.E., Prandi, D., Blattner, M., Chae, S.S., Dahija, A., Nataraj, S., Huang, D., Marotz, C., Xu, L., Huang, J., Lecca, P., Chhangawala, S., Liu, D., Zhou, P., Sboner, A., de Bono, J.S., Demichelis, F., Houvras, Y., Rubin, M.A. (2015) SPOP mutation leads to genomic instability in prostate cancer. eLIFE. 4
|
Butler, M.S., Roshan-Moniri, M., Hsing, M., Lau, D., Kim, A., Yen, P., Mroczek, M., Nouri, M., Lien, S., Axerio-Cilies, P., Dalal, K., Yau, C., Ghaidi, F., Guo, Y., Yamazaki, T., Lawn, S., Gleave, M.E., Gregory-Evans, C.Y., McIntosh, L.P., Cox, M.E., Rennie, P.S., Cherkasov, A. (2017) Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget. 8(26):42438-42454
|
Chen, L., Han, L., Mao, S., Xu, P., Xu, X., Zhao, R., Wu, Z., Zhong, K., Yu, G., Wang, X. (2021) Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer. European Journal of Medicinal Chemistry. 216:113307
|
Chen, Q., Cuello-Garibo, J.A., Bretin, L., Zhang, L., Ramu, V., Aydar, Y., Batsiun, Y., Bronkhorst, S., Husiev, Y., Beztsinna, N., Chen, L., Zhou, X.Q., Schmidt, C., Ott, I., Jager, M.J., Brouwer, A.M., Snaar-Jagalska, B.E., Bonnet, S. (2022) Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model. Chemical science. 13:6899-6919
|
Chiavacci, E., Rizzo, M., Pitto, L., Patella, F., Evangelista, M., Mariani, L., Rainaldi, G. (2015) The zebrafish/tumor xenograft angiogenesis assay as a tool for screening anti-angiogenic miRNAs. Cytotechnology. 67(6):969-75
|
Ferrari, M.G., Ganaie, A.A., Shabenah, A., Mansini, A.P., Wang, L., Murugan, P., Davicioni, E., Wang, J., Deng, Y., Hoeppner, L.H., Warlick, C.A., Konety, B.R., Saleem, M. (2020) Identifying and treating ROBO1-ve /DOCK1+ve prostate cancer: An aggressive cancer subtype prevalent in African American patients. The Prostate. 80(13):1045-1057
|
Ganaie, A., Beigh, F.H., Astone, M., Ferrari, M.G., Maqbool, R., Umbreen, S., Parray, A.S., Siddique, H.R., Hussain, T., Murugan, P., Morrissey, C., Koochekpour, S., Deng, Y., Konety, B.R., Hoeppner, L.H., Saleem, M. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models.. Clinical cancer research : an official journal of the American Association for Cancer Research. 24(24):6421-6432
|
Ghotra, V.P., He, S., van der Horst, G., Nijhoff, S., de Bont, H., Lekkerkerker, A., Janssen, R., Jenster, G., van Leenders, G.J., Hoogland, A.M., Verhoef, E.I., Baranski, Z., Xiong, J., van de Water, B., van der Pluijm, G., Snaar-Jagalska, E., Danen, E. (2015) SYK is a candidate kinase target for the treatment of advanced prostate cancer. Cancer research. 75(1):230-40
|
Grolez, G.P., Hammadi, M., Barras, A., Gordienko, D., Slomianny, C., Völkel, P., Angrand, P.O., Pinault, M., Guimaraes, C., Potier-Cartereau, M., Prevarskaya, N., Boukherroub, R., Gkika, D. (2019) Encapsulation of a TRPM8 Agonist, WS12, in Lipid Nanocapsules Potentiates PC3 Prostate Cancer Cell Migration Inhibition through Channel Activation. Scientific Reports. 9:7926
|
Manuelli, V., Cahill, F., Wylie, H., Gillett, C., Correa, I., Heck, S., Rimmer, A., Haire, A., Van Hemelrijck, M., Rudman, S., Wells, C.M. (2022) Invadopodia play a role in prostate cancer progression. BMC cancer. 22:386
|
Melong, N., Steele, S., MacDonald, M., Holly, A., Collins, C.C., Zoubeidi, A., Berman, J.N., Dellaire, G. (2017) Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia. Scientific Reports. 7(1):14698
|
Mushtaq, M., Jensen, L., Davidsson, S., Grygoruk, O.V., Andrén, O., Kashuba, V., Kashuba, E. (2018) The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells. Scientific Reports. 8:2268
|
Nouri, M., Caradec, J., Lubik, A.A., Li, N., Hollier, B.G., Takhar, M., Altimirano-Dimas, M., Chen, M., Roshan-Moniri, M., Butler, M., Lehman, M., Bishop, J., Truong, S., Huang, S.C., Cochrane, D., Cox, M., Collins, C., Gleave, M., Erho, N., Alshalafa, M., Davicioni, E., Nelson, C., Gregory-Evans, S., Karnes, R.J., Jenkins, R.B., Klein, E.A., Buttyan, R. (2017) Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget. 8:18949-18967
|
|
|
Xu, W., Foster, B.A., Richards, M., Bondioli, K.R., Shah, G., Green, C.C. (2017) Characterization of prostate cancer cell progression in zebrafish xenograft model. International Journal of Oncology. 52(1):252-260
|
Zoni, E., Chen, L., Karkampouna, S., Granchi, Z., Verhoef, E.I., La Manna, F., Kelber, J., Pelger, R.C., Henry, M.D., Snaar-Jagalska, E., van Leenders, G.J., Beimers, L., Kloen, P., Gray, P.C., van der Pluijm, G., Kruithof-de Julio, M. (2017) CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer. Oncogene. 36(33):4739-4749
|
